Expanded Access for CC-10004 NCT03740516

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: No longer available

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-10004.

Recruitment information / eligibility
Status	No longer available
Enrollment	0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender	All
Age group	N/A and older
Eligibility	Inclusion Criteria: - Exclusion Criteria: -

Drug:
• CC-10004
CC-10004 will be administered orally

Locations
Country	Name	City	State
United States	Celgene	Summit	New Jersey

Sponsors *(1)*
Lead Sponsor	Collaborator
Amgen

United States,